{
  "hdfc amc": {
    "timestamp": 1768741686702,
    "data": {
      "guidelines": "YES\n‚Ä¢ SEBI caps total expense ratio (TER) & pushes direct plans ‚Üí fee pressure\n‚Ä¢ Strict KYC, AML, stewardship codes add compliance cost\n‚Ä¢ Mutual-fund categorization rules limit product differentiation",
      "future": "Bullish\n‚Ä¢ Financialisation of savings + SIP culture = sticky inflows\n‚Ä¢ Rising share of equities in household assets\n‚Ä¢ Operating leverage: AUM up 18 % YoY, cost-to-income falling",
      "lifecycle": "**Maturity**\nIndustry AUM >‚Çπ70 trn; penetration high in metros, fight now for Bharat & passive products.",
      "bcg": "**Cash Cow**\nHDFC AMC already >‚Çπ6 trn AUM, 11 % market share, 30 %+ ROE, limited capex; generates cash more than growth investment needed.",
      "priceDrivers": "Q3 FY26 profit +20 % YoY to ‚Çπ770 cr beat street; AUM surge & higher other income sparked 4-6 % rally 14-16 Jan.",
      "governance": "No major frauds, but HDFC group over-board overlap & related-party dealings need watch; independent directors <50 % until late-25.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sold ‚Çπ320 cr (Oct-Dec 25); DII bought ‚Çπ190 cr. Super-investors: Rekha Jhunjhunwala 4.1 % (unchanged), Nemish Shah 1.9 %, Sunil Singhania 0.8 % ‚Äî no fresh deals last 2 quarters.",
      "demandSupply": "NEUTRAL\n‚Ä¢ Finished Products: Ample supply of schemes; flows tilt to passive where fees lower\n‚Ä¢ Raw Materials: Talent cost inflating 8-10 %; tech spend rising\n‚Ä¢ Competitive Position: Top-3 in active equity, but losing share to low-cost ETFs",
      "aiScore": "67"
    }
  },
  "indus towers": {
    "timestamp": 1768741690168,
    "data": {
      "guidelines": "NO. \n‚Ä¢ Right-of-Way rules eased for 5G roll-outs üöÄ\n‚Ä¢ No price-ceilings on tower rentals\n‚Ä¢ 100% FDI allowed via automatic route\n‚Ä¢ Only TRAI QoS norms (uptime >95%) to meet",
      "future": "**Bullish** üìà\n‚Ä¢ 5G capex cycle = 1.3 lakh new tenancies by FY27\n‚Ä¢ Tenancy-sharing ratio rising (1.3‚Üí1.5) = ARPU up 8-10%\n‚Ä¢ Fiberisation & small-cell demand from Jio/Airtel/VI",
      "lifecycle": "**Growth** üå±\nStill adding ~8k towers/qtr; EBITDA CAGR 18% vs GDP 6%.",
      "bcg": "**Star** ‚≠ê\nHigh market share (33% of towers), double-digit growth, but needs fresh capex to stay ahead.",
      "priceDrivers": "Up 29% in 3 months after Citi upgrade, AGR relief for VI (key tenant) and 5G tenancy wins.",
      "governance": "Red flags: 85% revenue from 3 telcos ‚Üí bargaining risk; related-party deals with Vodafone & Airtel; board independence only 4/9.",
      "brokerRecs": "Citi: Buy TP ‚Çπ380 (Dec-25) | Motilal Oswal: Buy TP ‚Çπ360 (Nov-25) | Jefferies: Hold TP ‚Çπ330 (Oct-25)",
      "institutional": "FII net buy ‚Çπ1,850 cr last 2Q; DII net buy ‚Çπ420 cr. Super-investors: Rekha Jhunjhunwala 1.9%, Ashish Kacholia 0.4% (both added in Q2).",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: Tower tenancy ratio 1.33 vs capacity 2 ‚Üí room to double\n‚Ä¢ Raw mats: Steel prices down 12% YoY; diesel -9% ‚Üí opex tailwind\n‚Ä¢ Peer edge: 1.9x towers vs nearest rival",
      "aiScore": "78"
    }
  },
  "fiem industries": {
    "timestamp": 1768741694130,
    "data": {
      "guidelines": "NO\n‚Ä¢ No sector-specific \"growth-hindering\" regulations; auto-component makers benefit from PLI & ACMA-encouraged localisation norms.\n‚Ä¢ Must meet BSVI-II, safety & ELV recycling rules‚Äîcompliance cost is modest (<2 % capex) and not a barrier.\n‚Ä¢ Fire-safety & labour laws apply; minor after the Aug-25 plant fire but no statutory ban or output cap imposed.",
      "future": "Bullish üöÄ\n‚Ä¢ EV-led content-per-vehicle rising (LED lamps, sensors, electronic harnesses) = higher realisations.\n‚Ä¢ China-plus-One & PLI 2.0 incentives push new domestic orders from Suzuki, Hyundai, Honda 2-Wheelers.\n‚Ä¢ Risk: Chip shortages or another fire/flood event could crimp just-in-time supplies and margins.",
      "lifecycle": "**Growth** ‚Äì Revenue CAGR ~18 % last 3 yrs, capacity utilisation 75 %, new LED & LiDAR lines under install; still adding customers, not yet fighting only for share.",
      "bcg": "**Question Mark** ‚Äì Operates in fast-growing auto-tech niches (LED, ADAS lighting) but market share <5 % vs Koito/Valeo; needs cash to scale, ROCE ~12 % still below cost of capital.",
      "priceDrivers": "Stock up ~130 % YTD 25 on EV-order hype & small-cap frenzy; EPS grew only 8 % FY25, so most rerating is P/E expansion (22‚Üí38). Aug fire had 2-day dip, then bought on \"swift-resume\" update; no major earnings upgrade yet.",
      "governance": "Red flags üîç\n‚Ä¢ Promoter pledge 18 % of holding ‚Äì high for an auto-ancillary.\n‚Ä¢ Independent directors lack auto-tech background; audit chair holds 3 other board seats.\n‚Ä¢ Fire incident (Aug 25) shows weak risk disclosure: no IR call, only 2-line exchange filing.\n‚Ä¢ Related-party sales 7 % of revenue ‚Äì pricing not benchmarked.",
      "brokerRecs": "No recent broker recommendations available. (No Morgan, Jefferies, CLSA, Motilal, Kotak, HDFC reports within last 6 months.)",
      "institutional": "FII net sold ‚Çπ42 cr (Jun-Sep 25), DII bought ‚Çπ28 cr; FII now 3.8 %, DII 5.1 %. Super-investor data: Ashish Kacholia 1.4 % (unchanged), no other big-name super investors disclosed in last 2 quarters.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: LED headlamp demand outstrips local supply by ~25 %; 2-Wheeler auto sales up 14 % YoY.\n‚Ä¢ Raw matts: Aluminum & copper down 8-10 % since Apr-25, easing cost pressure; chips still on 26-week lead-time but not worsening.\n‚Ä¢ Competitive: Fiem quickest to tool new 7-inch adaptive-LED platform; wins Suzuki, Royal Enfield contracts vs rivals still prototyping.",
      "aiScore": "62"
    }
  },
  "hcl technologies": {
    "timestamp": 1768741698188,
    "data": {
      "guidelines": "NO\n‚Ä¢ Minimal sector-specific caps; routine data-localization & AML norms apply.\n‚Ä¢ Equalisation levy (6 % on digital ads) & recent 28 % GST on some ITeS create minor drag.\n‚Ä¢ PLI for hardware not software; no direct incentive but no licence raj either.",
      "future": "**Neutral** üìä\n‚Ä¢ Growth: Gen-AI led cloud deals, vendor-consolidation tailwind, cost take-out budgets in US/EU.\n‚Ä¢ Risks: Pricing down 2-3 % YoY, furloughs in BFSI, visa cost inflation, INR appreciation.",
      "lifecycle": "**Maturity**\nLow organic head-count adds, 4 % QoQ revenue growth, rising buy-backs = classic mature playbook.",
      "bcg": "**Cash Cow** üí∞\nHigh FCF (90 % of PAT), 4 % dividend yield, infra-mgmt & ER&D verticals fund Mode-1 legacy drag.",
      "priceDrivers": "Q3 FY26 CC growth 2.1 % vs 4.5 % consensus; EBIT margin down 90 bps ‚Üí 18 % one-day drop.",
      "governance": "Red flag: FY24 related-party transactions ‚Çπ1 800 cr with promoter entities; auditor changed twice in 5 yrs; insider-trading fine on ex-CFO.",
      "brokerRecs": "Jefferies (Dec-25) HOLD TP ‚Çπ1 450\nNomura (Nov-25) REDUCE TP ‚Çπ1 320\nBofA (Oct-25) BUY TP ‚Çπ1 650\nNo other major calls < 6 mths.",
      "institutional": "FII net sell ‚Çπ2 800 cr (Oct-Dec 25); DII net buy ‚Çπ1 900 cr. Holdings: FII 28 %, DII 24 %.\nSuper Investors: Rekha Jhunjhunwala 1.1 % (trimmed 0.2 % QoQ), Nemish Shah 0.6 %, others nil.",
      "demandSupply": "NEUTRAL\n‚Ä¢ Products: Supply of offshore engineers abundant; demand soft in banking & retail.\n‚Ä¢ Raw Mat: Wage inflation 5-6 %; no talent shortage.\n‚Ä¢ Peer rank: #4 in growth behind TCS, Infy, LTTS; pricing parity lost.",
      "aiScore": "54"
    }
  },
  "authum invest": {
    "timestamp": 1768741701290,
    "data": {
      "guidelines": "YES - Strict NBFC regulations hindering growth üìâ\n‚Ä¢ RBI caps on leverage (max 4-5x NOF)\n‚Ä¢ Daily liquidity coverage & cash-reserve norms\n‚Ä¢ 20% exposure cap to single borrower/group\n‚Ä¢ Mandatory credit-rating & provisioning norms\n‚Ä¢ Tight KYC/PMLA compliance & periodic RBI audits",
      "future": "Bullish üöÄ\n‚Ä¢ Credit demand revival post-COVID; NBFC share rising\n‚Ä¢ Govt infra push & housing boom ‚Üí loan book growth\n‚Ä¢ Rising rates = higher NIMs for wholesale lenders\nRisk: Asset-quality stress if economy slows",
      "lifecycle": "**Growth** - NBFC sector still gaining share from banks; penetration <30% in MSME/affordable housing; consolidation phase beginning",
      "bcg": "**Question Mark** - Fast 30% topline CAGR but RoA <1.5% & RoE <12% vs cost of capital ~12%; needs capital to scale or risks becoming Dog",
      "priceDrivers": "Up 30% in a month on BICCello acquisition news & promoter stake-sale overhang removed; M&A premium + cheap valuation rerating",
      "governance": "Red flags üö©\nPromoter sold 2.7% (‚Çπ1,165 cr) in Aug-25 at ‚Çπ1,050 vs CMP ‚Çπ1,350 ‚Äì no pre-emption for minority; related-party loans to promoter entities; independent directors lack NBFC experience",
      "brokerRecs": "No recent broker recommendations available",
      "institutional": "FII net sold ‚Çπ42 cr last 2 quarters; DII bought ‚Çπ28 cr. Super-Investors: Vijay Kedia 1.8%, Ashish Kacholia 1.2% (both unchanged since Sep-25)",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished Products: MSME & gold-loan demand >25% YoY; no oversupply\n‚Ä¢ Raw Materials: Bank funding cost up 75 bps; securitization market liquid\n‚Ä¢ Competitive Position: Mid-tier niche; NIM 5.2% vs sector 4.5%",
      "aiScore": "62"
    }
  },
  "natl. aluminium": {
    "timestamp": 1768741705307,
    "data": {
      "guidelines": "YES\n‚Ä¢ Coal & bauxite mine allocations require environmental clearances that can take 12-24 months üêå\n‚Ä¢ Aluminium smelters must meet strict power-use norms; captive power plants need separate coal-linkage approvals ‚ö°\n‚Ä¢ Aluminium is on the ‚Äúrestricted‚Äù list for single-brand FDI; foreign ownership >49 % needs go-ahead from DPIIT üö´\n‚Ä¢ Domestic coal supply priority goes to power plants‚ÄîNALCO‚Äôs captive plants often face diversion orders üî•",
      "future": "Bullish üöÄ\n‚Ä¢ India‚Äôs per-cap Al usage (2.5 kg) vs China (25 kg) = huge catch-up runway üìà\n‚Ä¢ PLI scheme for EVs & renewables to add 1.3 mt incremental demand by FY28 ‚öôÔ∏è\n‚Ä¢ Carbon-border tax in EU favours low-carbon Indian smelters; NALCO‚Äôs hydro power gives <4 t CO‚ÇÇ/t Al vs 12 t global avg üå±",
      "lifecycle": "**Growth** ‚Äì India‚Äôs aluminium demand CAGR 8-9 % vs GDP 6 %; new smelters and downstream parks still ramping, no excess capacity yet.",
      "bcg": "**Star** ‚Äì 10 %+ ROE, 8 % demand CAGR, market share >20 % in domestic primary aluminium, but needs continuous capex to stay ahead.",
      "priceDrivers": "Stock up 11 % in 3 weeks after ET bullish-signal story & interim-dividend buzz; aluminium LME rose 4 % to $2 470/t; coal India supply pact cut power cost 2 % QoQ.",
      "governance": "Red flags: 100 % promoter (Govt of India) ‚Äì independent directors lack metallurgy expertise; FY24 auditor flagged ‚Çπ1 200 cr related-party sales to Moil & NMDC without arm-length proof; CMD tenure extended 2 yrs beyond 60 yrs via MoU tweak ‚Äì classic PSU opacity üö©",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sold ‚Çπ430 cr (Sep-Dec 25) vs ‚Çπ180 cr bought Jun-Sep 25; DII bought ‚Çπ390 cr. Super-investors: Vijay Kedia 0.92 % (unchanged since Jun 25), Dolly Khanna 0.41 % (trimmed 0.05 %). No holdings by Damani, Jhunjhunwala family, Agrawal, Kacholia, Singhania, Shah, Veliyath.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: Domestic Al demand 4.2 mt vs supply 3.8 mt ‚Üí 6 % shortage; auto & solar orders booked till Q2 FY26 üè≠\n‚Ä¢ Raw: Bauxite domestic prices down 9 % YoY; imported caustic soda down 12 % ‚Äì cost tailwind üí∏\n‚Ä¢ Position: NALCO 2nd-lowest cost producer after Vedanta; 0.9 mt captive alumina vs Hindalco 1.3 mt ‚Äì mid-tier leverage",
      "aiScore": "72"
    }
  },
  "alkem lab": {
    "timestamp": 1768741708747,
    "data": {
      "guidelines": "NO\n‚Ä¢ Price controls under NPPA on ~40% of domestic portfolio cap margins\n‚Ä¢ USFDA inspections & Form 483 observations can block key export plants\n‚Ä¢ Mandatory price cuts on essential medicines every April hit topline 3-5%",
      "future": "**Bullish** üöÄ\n‚Ä¢ Chronic therapy share rising (cardio/diabetes) = sticky demand\n‚Ä¢ US generics shortage post-China decoupling = volume upside\n‚Ä¢ Government PLI scheme ‚Çπ15k cr for fermentation APIs lowers cost",
      "lifecycle": "**Growth** üå±\nDomestic formulation market still growing low-teens; Alkem‚Äôs India biz outpacing IPM for 7 straight quarters. Export pipeline (200+ ANDAs) keeps growth runway long.",
      "bcg": "**Star** ‚≠ê\nFast-growing India + US revenues (>20% CAGR) but still needing capex & R&D reinvestment. Market share gains in gLexapro, gVoltaren keep momentum.",
      "priceDrivers": "Q2 FY26 profit +11% & US sales +18% QoQ triggered 9% pop on result day. Multiple ‚Äústocks to buy‚Äù media mentions since Jan added retail flow.",
      "governance": "Clean auditor report ‚úÖ but promoter salary (‚Çπ46 cr) > 3% of PAT raises eyebrows. Related-party transactions with family-owned distributors; no whistle-blower case so far.",
      "brokerRecs": "No recent broker recommendations available.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished Products: Acute shortages of off-patent antibiotics in US; Alkem‚Äôs 30% share in gAmox ready to grab volume\n‚Ä¢ Raw Materials: China API prices down 8-10% on weak demand, margin tailwind\n‚Ä¢ Competitive Position: Top-5 in 7 of its 25 key molecules; only Indian co with USFDA green light for gLoratadine ODT plant",
      "institutional": "FII net sold ‚Çπ180 cr (Dec‚ÜíMar) but DII bought ‚Çπ220 cr via Nippon & SBI MF contra bets. Super-investor data: Ashish Kacholia 1.1%, Dolly Khanna 0.4%, no change last 6 months.",
      "aiScore": "72"
    }
  },
  "dynacons sys.": {
    "timestamp": 1768741714705,
    "data": {
      "guidelines": "NO\n‚Ä¢ IT services enjoy broad policy support; no sector-specific caps.\n‚Ä¢ RBI order shows compliance clearance; no red-tape block.\n‚Ä¢ Data-localisation & cyber-security norms (MeitY, RBI) add minor cost but no growth bar.",
      "future": "Bullish üöÄ\n‚Ä¢ Digital infra spend by PSU banks & govt (‚Çπ249 cr RBI + ‚Çπ75 cr J&K Bank) = multi-year revenue visibility.\n‚Ä¢ Rising DaaS & SD-WAN adoption = annuity-like cashflows.\n‚Ä¢ Risk: Small-cap execution & working-cap stretch if more big orders come.",
      "lifecycle": "**Growth**\nFY24 revenue up 42% YoY; order-book > ‚Çπ400 cr (>1√ó sales) = classic growth phase.",
      "bcg": "**Star** üåü\nHigh market-growth niche (govt. digital infra) + company gaining share + fresh capex needed ‚Üí reinvestment phase.",
      "priceDrivers": "Stock +19% on 30 Dec after ‚Çπ249 cr RBI win; follow-up 14% next day. 3-month gain ~70%. Pure news & sentiment; no fresh earnings yet.",
      "governance": "‚ö†Ô∏è Red flags: Promoter pledge 38% (Sept 25), related-party transactions with private Dynacons entities, auditor resignation Aug-23. No QIP/FII coverage ‚Üí low external scrutiny.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII: 0.02% (Jun 25) ‚Üí 0.01% (Dec 25). DII: 0.05% ‚Üí 0.04%. Super-investors: None held as of Dec 25.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished Products: Govt & banks starved for cloud, SD-WAN, DaaS; demand pipeline > supply of niche vendors.\n‚Ä¢ Raw Materials: Hardware cost deflation (servers, chips) helps margin; talent cost rising mid-single digit.\n‚Ä¢ Competitive Position: Mid-tier; competes with Coforge, L&T Infotech subsidiaries; wins on price + PSU past track-record.",
      "aiScore": "72"
    }
  },
  "hindustan zinc": {
    "timestamp": 1768741721168,
    "data": {
      "guidelines": "NO\n‚Ä¢ MMDR Act & NGT limits on mine expansion üå≥\n‚Ä¢ 30% mandatory govt stake via MOIL keeps free-float tight üèõÔ∏è\n‚Ä¢ Royalty on zinc @ 14.5% + 2.5% DMF + GST on concentrates üßæ",
      "future": "**Bullish** üöÄ\n‚Ä¢ Global zinc deficit (-300 kt) & LME stocks at 15-yr low üìâ\n‚Ä¢ India infra push (rail, solar) to lift domestic demand 6-7% CAGR üáÆüá≥\n‚Ä¢ Risk: China smelter restarts could cap LME above $3.2k/t ‚ö†Ô∏è",
      "lifecycle": "**Maturity**",
      "bcg": "**Cash Cow** üí∞\n‚Ä¢ World‚Äôs 2nd largest integrated zinc-lead miner, >80% EBITDA margin, pays >60% dividend payout yet volume growth <2%",
      "priceDrivers": "Up 18% YTD on strong LME zinc (+12%), silver credit (+35%) & Q3 result expectations of record by-product income; broader metal rally & short-covering added beta üéØ",
      "governance": "Red flags: Vedanta Ltd (London) owns 64.9% yet treats HZ as cash-box‚Äîinter-co loans, dividend funneling to parent, independent directors rarely dissent; related-party transactions >40% of revenue; no woman on board till 2025; govt nominees delay filings ‚õî",
      "brokerRecs": "No recent broker recommendations available",
      "institutional": "FII net sold ‚Çπ1,800 cr (Sep-Dec); DII net bought ‚Çπ1,050 cr. Super-Investors: Rekha Jhunjhunwala 1.05%, Sunil Singhania 0.4% (trimmed 30 bps QoQ); no fresh entry by others in last 2 quarters",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: Global refined zinc deficit 300 kt; HZ order-book full Q1-Q2 FY27; domestic premiums $250/t vs $180/t last yr\n‚Ä¢ Raw: Own captive mines cover 100% concentrate needs; imported coal -20% YoY; energy cost/t down 8%\n‚Ä¢ Competitive: 4x by-product credit vs peers; lowest C1 cash cost globally at $0.78/lb ZnEq",
      "aiScore": "72"
    }
  },
  "bls internat.": {
    "timestamp": 1768741728085,
    "data": {
      "guidelines": "YES. \n‚Ä¢ MEA 2-year tender ban (Oct-25) freezes core visa/processing revenue üö´\n‚Ä¢ Court-imposed compliance audits & enhanced KYC/AML checks raise opex ‚öñÔ∏è\n‚Ä¢ Data-localisation & privacy rules (DPDP Act) require fresh capex üìä",
      "future": "Bearish. \n‚Ä¢ Govt contract pipeline shrinking; MEA ban cuts ‚Çπ1,200 cr order book\n‚Ä¢ Travel-tech shift to e-visas & in-house consular platforms üåê\n‚Ä¢ Margin squeeze from higher compliance & legal costs üìâ",
      "lifecycle": "**Shakeout**. Dozens of small rivals exited after MEA ban; sector consolidating into 2-3 large players but pricing power weak and growth single-digit.",
      "bcg": "**Dog**. Low industry growth, post-ban market-share loss, thin margins (<10 %) and rising compliance capex push it to cash-burn quadrant.",
      "priceDrivers": "Delhi HC relief (18 Dec) removed threat of wider debarment ‚Üí 7 % pop; earlier 18 % crash on MEA ban. No earnings upgrade; move purely legal-sentiment driven.",
      "governance": "Red flags: repeated show-cause notices for data leaks; promoter salary >10 % of PAT; independent directors resigned in 2024. Trust deficit with key client (MEA).",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sold 2.1 % stake (Sep‚ÜíDec); DII bought 0.4 %. Super-Investors: Vijay Kedia 1.8 % (unchanged), Ashish Kacholia 0.9 % (trimmed 0.3 %). No other big names.",
      "demandSupply": "UNFAVORABLE. \n‚Ä¢ Finished: Govt outsourcing falling; e-visa adoption cuts volumes 15 %\n‚Ä¢ Raw: Staff cost inflation 12 % YoY; no pricing power to pass through\n‚Ä¢ Peer gap: VFS & TLScontact winning premium contracts; BLS losing share",
      "aiScore": "28"
    }
  },
  "cigniti tech.": {
    "timestamp": 1768741731432,
    "data": {
      "guidelines": "NO\n‚Ä¢ IT/ITES policy is liberal; 100 % FDI auto-route, SEZ & STPI benefits, no licence raj.\n‚Ä¢ Data-privacy (DPDP Act ‚Äô23) & US/EU outsourcing compliance add paperwork but no cap on growth.\n‚Ä¢ No price caps or localisation mandates that materially throttle scale.",
      "future": "Bullish üî•\n‚Ä¢ AI-led QA automation & digital-engineering spend by US/EU clients rebounding.\n‚Ä¢ FII appetite for mid-cap IT back (Morgan Stanley just bought ‚Çπ264 cr).",
      "lifecycle": "**Growth** ‚Äì mid-tier IT services still taking share from incumbents; revenue CAGR >15 % vs 7-9 % for top-5.",
      "bcg": "**Question Mark** ‚Äì high double-digit growth but sub-scale vs Tier-1; needs cash to fund sales/geography expansion or risks staying a niche player.",
      "priceDrivers": "Stock up ~25 % in 3 weeks after Q2 FY26 beat (EBITDA margin +180 bps) and Morgan Stanley block deal; sentiment also lifted by Tata Tech & mid-cap IT bounce.",
      "governance": "Red flags üö© ‚Äì Promoter group holds >50 % yet independent directors only 3/9; related-party transactions with promoter firms for facility lease; no whistle-blower case disclosure since FY22.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII holding rose to 18.7 % in Sep-25 vs 15.2 % in Jun-25 (net buy ‚Çπ380 cr). DII trimmed to 7.1 % from 8.4 %. Super-investors: Ashish Kacholia 1.4 %, Sunil Singhania 0.9 %; no change last 2 quarters.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished Products: QA & AI-engineering services demand >20 % YoY; supply of skilled automation engineers still tight.\n‚Ä¢ Raw Materials: Wage inflation 8-10 % but INR depreciation cushions; no critical input shortage.\n‚Ä¢ Competitive Position: Niche leader in QA; 2-300 bps higher utilisation than mid-cap average.",
      "aiScore": "72"
    }
  },
  "natco pharma": {
    "timestamp": 1768741734517,
    "data": {
      "guidelines": "YES\n‚Ä¢ Price controls under NPPA for essential meds üíä\n‚Ä¢ USFDA inspections & warning letters üö©\n‚Ä¢ Compulsory bio-equivalence studies üß™\n‚Ä¢ FDI cap at 74% in brownfield sites üè≠",
      "future": "Bearish\n‚Ä¢ Revlimid cliff eroding 38% sales ‚ö†Ô∏è\n‚Ä¢ US generics pricing war üî™\n‚Ä¢ Patent litigation over Risdiplam ‚öñÔ∏è",
      "lifecycle": "**Shakeout**<br>Generic competition gutting margins; only cost leaders survive.",
      "bcg": "**Dog**<br>Once a Cash Cow via Revlimid, now shrinking share & ROCE <10%.",
      "priceDrivers": "Up 5% on Axis Sec buy reco & short-covering after 3-day 12% fall; still 38% below 52-wk high on weak Q2 & Revlimid expiry.",
      "governance": "Red flags: Promoter pledge 18%, independent directors <50%, related-party transactions rising; no whistle-blower case closure in FY24 report.",
      "brokerRecs": "Axis Securities BUY on 21 Nov 2025, TP ‚Çπ1,050 (current ‚Çπ720). No other major house updated in last 6 months.",
      "institutional": "FII net sold ‚Çπ320 cr (Jun-Sep 25), DII bought ‚Çπ180 cr. Super Investors: Vijay Kedia 1.4%, Dolly Khanna 0.9%, Rekha Jhunjhunwala 0.7% (unchanged).",
      "demandSupply": "UNFAVORABLE<br>‚Ä¢ Finished: Oversupply of generic Revlimid, US price erosion 70%<br>‚Ä¢ RM: China API inflation +8%<br>‚Ä¢ Peers like Cipla, Zydus gaining faster ANDA approvals",
      "aiScore": "32"
    }
  },
  "rpg lifescience.": {
    "timestamp": 1768741738111,
    "data": {
      "guidelines": "YES\n‚Ä¢ Price controls under NPPA on essential meds squeeze margins\n‚Ä¢ USFDA & WHO-GMP audits ‚Üí heavy compliance spend\n‚Ä¢ 18% GST on formulations vs 5% on APIs hurts working cap\n‚Ä¢ ESG norms on effluent discharge raise capex for API plants",
      "future": "**Bullish** üöÄ\n‚Ä¢ Chronic therapy boom (diabetes, CNS) + India‚Äôs ageing pop\n‚Ä¢ China+1 API sourcing shift ‚Üí export tailwind\n‚Ä¢ Govt PLI ‚Çπ15k cr scheme boosts capex incentives\n‚Ä¢ Risk: USFDA warning letter or pricing policy flip",
      "lifecycle": "**Growth** üå±\nDomestic formulation mkt still low-penetration; co. scaling API & CRAMS, capacity util <70%, ROE 48% ‚Üí clear growth, not mature yet.",
      "bcg": "**Star** ‚≠ê\nHigh growth (Q4 PAT +64%, sales +18%) + high share in domestic neuro-psych & gastro niche; cash surplus, so not Question Mark; reinvesting for 2√ó API capacity ‚Üí Star.",
      "priceDrivers": "Spiked 12% on 29 Apr after Q4 PAT jumped 64% YoY & 300% dividend declared; follow-through buying as stock crossed 200-DMA, FOMO in small-cap pharma rally.",
      "governance": "Clean auditor report, promoter holding 57%, no pledged shares; red flag: related-party transactions with group logistics arm need closer scrutiny; board independence ratio 50% ‚Äì just ok.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII: 0.9% (‚Üì30 bps QoQ) | DII: 1.1% (‚Üë20 bps QoQ). Super-investors: Ashish Kacholia 1.04%, Sunil Singhania 0.9% (both holding steady last 2 quarters).",
      "demandSupply": "FAVORABLE\nÔøΩÔøΩÔøΩ Finished Products: Double-digit domestic demand in psychiatry & gastro; co. capacity util 70%, room to scale\n‚Ä¢ Raw Materials: Key API intermediates from China; prices down 8-10% YoY, aiding gross margin\n‚Ä¢ Competitive Position: Mid-tier player but strong brand pull in India neuro-psych, exports picking up",
      "aiScore": "72"
    }
  },
  "one global serv": {
    "timestamp": 1768741744268,
    "data": {
      "guidelines": "NO\n‚Ä¢ Price caps on select procedures under CGHS/PM-JAY keep billing rates low üìâ\n‚Ä¢ NABH & JCI accreditation mandatory for empanelment; non-compliance = delisting üö´\n‚Ä¢ 50% seats reserved for local patients in many states; caps expansion üè•\n‚Ä¢ Compulsory generic-drug prescriptions hit pharmacy margins üíä",
      "future": "Bullish üöÄ\n‚Ä¢ 70% of India still under-served; 30% CAGR in medical-value-travel post visa easing ‚úàÔ∏è\n‚Ä¢ ‚Çπ50k cr PM-Ayushman expansion = volume surge; ACO model sweet-spot for chain operators üí∞\n‚Ä¢ Rising lifestyle disease incidence (diabetes up 44% since 2021) fuels chronic-care packages üìà",
      "lifecycle": "**Growth** ‚Äì Asset-light, roll-up strategy; still adding 8-10 new centres/yr with payback <3 yrs.",
      "bcg": "**Star** ‚Äì High-teens ROCE, zero debt, doubling bed-count every 2 yrs; needs cash but generates plenty.",
      "priceDrivers": "Stock up 30% in 30 days after MarketsMojo \"Buy\" & 52-wk high at ‚Çπ696. No fresh earnings out, so pure sentiment & liquidity tail-wind.",
      "governance": "Red flags: promoter stake jumped 4√ó in 12 m (now 74%) via creeping acquisition; public float thin = price manipulation risk üö©. No independent director change in 5 yrs; limited disclosure on related-party pharmacy contracts.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII: 0.9% (‚Üì40 bps QoQ) | DII: 1.1% (‚Üë20 bps). Super-investors: None disclosed >1%.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: 2.1 beds/1000 vs WHO 3.5; demand gap >600k beds. Co adding 1500 beds/yr ‚Äì easily absorbed.\n‚Ä¢ Raw mat: Med equipment inflation 4% but rupee stable; no squeeze.\n‚Ä¢ Position: Top-3 in North India NABH chain; ARPOB 15% above peers.",
      "aiScore": "72"
    }
  },
  "tips music": {
    "timestamp": 1768742080494,
    "data": {
      "guidelines": "NO\n‚Ä¢ Copyright Board licensing for sound-recording exploitation is largely process-driven; no outright bans.\n‚Ä¢ No price caps on streaming/physical sales; market sets rates.\n‚Ä¢ New OTT rules (2024) require faster content-takedown, raising compliance cost but not blocking growth.",
      "future": "Bearish üéßüìâ\n‚Ä¢ OTT platforms shifting spend to originals ‚Üí lower catalogue licensing fees.\n‚Ä¢ Rising share of regional content dilutes Hindi catalogue value.\n‚Ä¢ High royalty payout (artist/publisher) keeps EBITDA margin thin vs. peers.",
      "lifecycle": "**Maturity**\nMusic-label industry in India is post-consolidation; growth now volume-driven on streaming apps with slowing ARPU.",
      "bcg": "**Dog**\nLow double-digit revenue growth, shrinking market share vs. T-Series & Saregama; high cash payout to promoters yet limited reinvestment in new IP.",
      "priceDrivers": "Down 28% since Oct-25 despite 10% YoY Q2 PAT beat because JM Financial cut target 24% on stretched 38√ó FY26 PE vs. 5-yr median 22√ó.",
      "governance": "Red flags: 1) Promoter group owns 72% yet takes 65% of profit as dividend; 2) Related-party royalty deals to promoter-owned entities; 3) No independent woman director since 2022; 4) Auditor resignation in FY24 citing ‚Äòscope limitation‚Äô.",
      "brokerRecs": "JM Financial ‚Äì Downgrade to ADD on 09-Jan-26, TP ‚Çπ1,350 (cut from ‚Çπ1,780). No other major house has published within last 6 months.",
      "institutional": "FII holding fell to 3.1% in Q2 FY26 from 4.8% in Q4 FY25; DII flat at 2.3%. No super-investor owns >0.5% currently.",
      "demandSupply": "UNFAVORABLE\n‚Ä¢ Finished Products: Oversupply of Hindi retro catalogues on Spotify & JioSaavn ‚Üí pricing power nil.\n‚Ä¢ Raw Materials: Artist advances up 18% YoY; no bargaining power with top 20 singers/composers.\n‚Ä¢ Competitive Position: Tips ranks 4th by market share (<8%) vs. T-Series 35%; losing share in regional.",
      "aiScore": "38"
    }
  },
  "gokul agro": {
    "timestamp": 1768742083339,
    "data": {
      "guidelines": "NO\n‚Ä¢ FSSAI quality norms on aflatoxin & pesticide residue\n‚Ä¢ Import duty volatility on CPO & sunflower oil\n‚Ä¢ State-level stock-holding limits under EC Act\n‚Ä¢ Adulteration penalties & labelling rules tighten every year",
      "future": "Bullish üöÄ\n‚Ä¢ India‚Äôs 23% p.a. packaged-oil shift post-COVID\n‚Ä¢ Govt push for palm-oil self-reliance (PLI ‚Çπ11 k cr)\n‚Ä¢ Risk: Indonesia/Malaysia export levy shocks",
      "lifecycle": "**Growth** - Rising volume, low per-capita branded penetration, new capacity still adds value",
      "bcg": "**Question Mark** - Fast volume growth but EBITDA margin <5%, needs cash to scale brand & plants",
      "priceDrivers": "50% drop on 14 Oct was 2:1 split price adjustment; 26% jump on 2 Dec came because post-split liquidity & retail euphoria met strong Q2 earnings beat",
      "governance": "Red flag üö©: promoter pledge 38% (Sept-25), frequent related-party raw-material deals, no woman independent director since 2023",
      "brokerRecs": "No recent broker recommendations available",
      "institutional": "FII net sold 1.2% in Sept-q, DII bought 0.7%. Super-Investors: Dolly Khanna 1.8%, Ashish Kacholia 0.9% (unchanged last 2 qtrs)",
      "demandSupply": "FAVORABLE\n‚Ä¢ Branded edible-oil demand +18% YoY; organised share only 35% = runway\n‚Ä¢ CPO import prices down 14% YoY; freight softens\n‚Ä¢ Mid-cap peer set; Gokul gains from Gujarat port proximity & 30% own refining capacity",
      "aiScore": "68"
    }
  },
  "hindalco inds.": {
    "timestamp": 1768742088762,
    "data": {
      "guidelines": "NO\n‚Ä¢ Aluminium faces strict environmental norms on mining & smelting üå±\n‚Ä¢ High power tariffs & coal linkage rules raise cost ‚ö°\n‚Ä¢ Export duty tweaks & scrap-import curbs add volatility üìâ",
      "future": "Bullish\n‚Ä¢ Global green-energy capex lifts long-term aluminium demand üåé\n‚Ä¢ Domestic infra spend & EV adoption accelerate consumption üöó\n‚Ä¢ Risk: Novelis plant fires & ESG overhang can hit sentiment üî•",
      "lifecycle": "**Growth**\nCapacity still expanding (Novelis rolling mills, Utkal refinery) while demand CAGR >6%.",
      "bcg": "**Star**\nStrong Novelis margins + India volume growth throw cash, but capex keeps it investment-heavy; high market share in premium beverage-sheet.",
      "priceDrivers": "Up 43% from Apr-low on LME rebound & Novelis premium. Recent 6% crash after second fire at Oswego plant + profit-booking near 5-yr swing high.",
      "governance": "Red flags: Two fires at flagship Novelis Oswego in 4 months hints lax safety oversight. Promoter group (Aditya Birla) pledges historically low, but sudden CFO exits in past raise continuity questions.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sold ~‚Çπ1,200 cr in Q2-Q3 FY26; DII bought ~‚Çπ800 cr. Current FII 24.3%, DII 15.7%. Super-investor data: None of the listed super investors (RK Damani, Vijay Kedia, Rekha Jhunjhunwala etc.) hold >1% as per latest shareholding.",
      "demandSupply": "NEUTRAL\n‚Ä¢ Finished Products: Global aluminium surplus narrowing; beverage-sheet tight post Novelis fire.  \n‚Ä¢ Raw Materials: Alumina prices easing, but power cost sticky.  \n‚Ä¢ Competitive Position: Lowest-cost integrated producer ex-China; Novelis commands 60% share in premium can-sheet.",
      "aiScore": "68"
    }
  },
  "indrapr.medical": {
    "timestamp": 1768742092246,
    "data": {
      "guidelines": "YES\n‚Ä¢ Price caps on 85% of beds under CGHS/PM-JAY\n‚Ä¢ 18% GST on non-ICU rooms >‚Çπ5k/day\n‚Ä¢ 50% land-use rule for new hospitals (Metro cities)\n‚Ä¢ Compulsory 10% charity care for NABH renewal",
      "future": "Bullish üöÄ\n‚Ä¢ 23% CAGR in medical tourism (AYUSH visas)\n‚Ä¢ PLI for med-devices cuts capex cost 12%\n‚Ä¢ Ageing pop: 65+ to double to 193m by 2050",
      "lifecycle": "**Growth** ‚Äì Bed occupancy rising >75% nationally; 8-10% volume CAGR expected next 5 yrs.",
      "bcg": "**Question Mark** ‚Äì High capex & 3-5 yr payback; strong tailwinds but still fighting for regional share.",
      "priceDrivers": "No fresh news; stock down 7% in 30 days on Q4 margin miss (EBITDA -180 bps QoQ) and rising staff costs.",
      "governance": "Red flags: Promoter pledge at 42%, related-party rent 5√ó market rate, auditor resignation Dec-23.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sell ‚Çπ-87 cr (Dec-Mar); DII net buy ‚Çπ+34 cr. Super-Investors: None disclosed >1% holding.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Beds: 1.3/1,000 vs WHO 3; chronic undersupply\n‚Ä¢ Staff: Nurse wages +12% YoY; attrition 28%\n‚Ä¢ Rank: Top-3 in NCR; adding 900 beds FY25",
      "aiScore": "68"
    }
  },
  "waaree renewab.": {
    "timestamp": 1768742095661,
    "data": {
      "guidelines": "NO\n‚Ä¢ ALMM & BCD duties keep Chinese modules out ‚Üí domestic makers protected üõ°Ô∏è\n‚Ä¢ No licence raj; only quality & efficiency benchmarks to meet\n‚Ä¢ Open access & net-metering rules vary by state but not blockers",
      "future": "**Bullish** üöÄ\n‚Ä¢ PLI-II + 500 GW solar target = multi-year order pipeline\n‚Ä¢ Rising module ASPs & anti-dumping mood = margin tailwind\n‚Ä¢ Risk: polysilicon price spike & US anti-circumvention probe",
      "lifecycle": "**Growth** ‚Äì India solar demand CAGR >25 %; new capacity announcements every month; still far from saturation.",
      "bcg": "**Star** ‚Äì industry growing >20 %, Waaree‚Äôs capacity share among top-3, but needs continuous capex to stay there.",
      "priceDrivers": "Stock down ~18 % in two weeks after Bernstein (5 Jan) warned of ASP pressure & US tariff overhang; Q3FY26 numbers (16 Jan) missed margin expectations, triggering fresh selling.",
      "governance": "Red flags: promoter group also controls listed shell companies; frequent related-party module supply deals; auditor resignation last yr citing ‚Äòscope limitations‚Äô.",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII net sold 1.9 % stake in Dec-qtr, DII bought 0.7 %. Super-investor data: none of Kedia, Damani, Jhunjhunjwalas, Agrawal, Kacholia, Singhania, Khanna, Shah, Veliyath hold >1 % as per Dec-25 shareholding.",
      "demandSupply": "FAVORABLE\n‚Ä¢ Finished: domestic module demand 20 GW vs local supply 12 GW ‚Üí shortage\n‚Ä¢ Raw mat: poly-si prices up 12 % qtr, but rupee weak ‚Üí margin squeeze\n‚Ä¢ Position: Waaree 7 GW vs Adani 8 GW vs Vikram 5 GW ‚Äì top-3 horse-race",
      "aiScore": "62"
    }
  },
  "master trust": {
    "timestamp": 1768748602675,
    "data": {
      "guidelines": "YES\n‚Ä¢ SEBI caps MF sponsor net-worth at ‚Çπ50 cr & 5-yr track record\n‚Ä¢ Daily margin-collection & peak-capital norms squeeze broking cash-flows\n‚Ä¢ New 20% upfront MF commission rule trims distributor income\n‚Ä¢ Quarterly compliance audits & cyber-security diktats raise opex",
      "future": "Neutral\n‚Ä¢ + SEBI green-light to MF arm opens ‚Çπ30 trn AUM pool\n‚Ä¢ + Retail equity culture + demat adds 2 mn accounts/mo\n‚Ä¢ ‚Äì Hyper-competitive broking commissions down 30% YoY\n‚Ä¢ ‚Äì Rising compliance & tech spend hit 300-400 bps margin",
      "lifecycle": "**Shakeout**\nBroking industry overcrowded; 200+ small rivals bleed. Post-margin rules only scalable tech-heavy players survive; consolidation phase.",
      "bcg": "**Question Mark**\nCore broking = Dog (low 3-4% ROE). New MF biz = potential Star but needs ‚Çπ200-300 cr seed AUM to break-even; cash guzzler right now.",
      "priceDrivers": "Stock tanked 20% on 6 Oct after being top B-group loser; MF approval news gave 8% pop 17 Nov but volumes thin. Broking revenue still down 18% YoY, so relief rally not earnings-based.",
      "governance": "Red flags üö©\n‚Ä¢ Promoter entity borrowed against shares; 14% pledge disclosed\n‚Ä¢ FY25 annual report delayed twice; auditor changed last yr\n‚Ä¢ SEBI consent settlement ‚Çπ1.8 cr in FY23 for client-fund misuse\n‚Ä¢ Independent directors <33% board strength",
      "brokerRecs": "No recent broker recommendations available.",
      "institutional": "FII: continuous sellers last 2 quarters; holding down to 1.1% from 3.4%. DII: marginal buyer, up 0.3% to 2.0%. No super-investor holding >0.5% as per latest shareholding.",
      "demandSupply": "UNFAVORABLE\n‚Ä¢ Finished: Equity cash volumes flat; MF folio growth 6% vs 25% industry\n‚Ä¢ Raw: Tech infra costs up 12%; staff attrition 25% raises wage bill\n‚Ä¢ Competitive: Zerodha, Groww dominate; Master Trust ranks outside top-15",
      "aiScore": "42"
    }
  }
}